Skip to main content
Top
Published in: Diabetologia 7/2015

Open Access 01-07-2015 | Article

Cardiovascular risk factors and cognitive decline in older people with type 2 diabetes

Authors: Insa Feinkohl, Markéta Keller, Christine M. Robertson, Joanne R. Morling, Stela McLachlan, Brian M. Frier, Ian J. Deary, Mark W. J. Strachan, Jackie F. Price

Published in: Diabetologia | Issue 7/2015

Login to get access

Abstract

Aims/hypothesis

The aim of this work was to assess the role of well-established cardiovascular risk factors in the late-life cognitive decline of patients with type 2 diabetes.

Methods

Data from 831 participants (aged 60–75 years) attending the 4 year follow-up of the Edinburgh Type 2 Diabetes Study (ET2DS) were used. Smoking history (pack-years), BP, HbA1c, plasma glucose and cholesterol were determined at baseline clinics (single time measurements) and/or from serial data recorded on a clinical management database from diagnosis until recruitment (‘historical’ data). Principal component analysis derived a factor, g, of general ability from seven cognitive tests. Linear regression models of follow-up g were adjusted for baseline g to represent 4 year cognitive change. ‘Accelerated late-life cognitive decline’ was defined as scoring in the lowest tertile of ‘4 year cognitive change’ regression scores. Analyses controlled for age and sex.

Results

A baseline history of moderate/heavy smoking (≥10 pack-years) and a 1% increased historical HbA1c (equivalent to an increase by 11 mmol/mol) predicted a 64% (OR 1.64; 95% CI 1.14, 2.34; p = 0.007) and 21% (OR 1.21; 95% CI 1.00, 1.45; p = 0.046) increased risk of accelerated cognitive decline, respectively. When treated as continuous measures, higher pack-years, historical HbA1c and historical BP emerged as significant independent predictors of 4 year decline in g (standardised β range −0.07 to −0.14; all p ≤ 0.05).

Conclusions/interpretation

Increased smoking and poorer glycaemic control (with relatively weaker findings for BP) during the life-course were independently associated with accelerated late-life cognitive decline. Where possible, evaluation is warranted of these risk factors as targets for intervention to reduce the burden of cognitive impairment in diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 48:2460–2469PubMedCrossRef Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes–systematic overview of prospective observational studies. Diabetologia 48:2460–2469PubMedCrossRef
2.
go back to reference UnitedHealth Center for Health Reform & Modernization (2010) The United States of Diabetes: challenges and opportunities in the decades ahead. United Health Group, Minnetonka UnitedHealth Center for Health Reform & Modernization (2010) The United States of Diabetes: challenges and opportunities in the decades ahead. United Health Group, Minnetonka
3.
go back to reference Takeda S, Sato N, Rakugi H, Morishita R (2011) Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst 7:1822–1827PubMedCrossRef Takeda S, Sato N, Rakugi H, Morishita R (2011) Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol Biosyst 7:1822–1827PubMedCrossRef
4.
go back to reference Jackson K, Barisone GA, Diaz E, Jin L-W, DeCarli C, Despa F (2013) Amylin deposition in the brain: a second amyloid in Alzheimer’s disease? Ann Neurol 74:517–526PubMedCrossRef Jackson K, Barisone GA, Diaz E, Jin L-W, DeCarli C, Despa F (2013) Amylin deposition in the brain: a second amyloid in Alzheimer’s disease? Ann Neurol 74:517–526PubMedCrossRef
5.
go back to reference Feinkohl I, Keller M, Robertson CM et al (2013) Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 36:2779–2786PubMedCentralPubMedCrossRef Feinkohl I, Keller M, Robertson CM et al (2013) Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 36:2779–2786PubMedCentralPubMedCrossRef
6.
go back to reference Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63:658–663PubMedCrossRef Yaffe K, Blackwell T, Kanaya AM, Davidowitz N, Barrett-Connor E, Krueger K (2004) Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 63:658–663PubMedCrossRef
7.
go back to reference Okusaga O, Stewart MC, Butcher I, Deary IJ, Fowkes FGR, Price JF (2013) Smoking, hypercholesterolaemia and hypertension as risk factors for cognitive impairment in older adults. Age Ageing 42:306–311PubMedCrossRef Okusaga O, Stewart MC, Butcher I, Deary IJ, Fowkes FGR, Price JF (2013) Smoking, hypercholesterolaemia and hypertension as risk factors for cognitive impairment in older adults. Age Ageing 42:306–311PubMedCrossRef
8.
go back to reference Stewart MCW, Deary IJ, Fowkes FGR, Price JF (2006) Relationship between lifetime smoking, smoking status at older age and human cognitive function. Neuroepidemiology 26:83–92PubMedCrossRef Stewart MCW, Deary IJ, Fowkes FGR, Price JF (2006) Relationship between lifetime smoking, smoking status at older age and human cognitive function. Neuroepidemiology 26:83–92PubMedCrossRef
9.
go back to reference Richards M, Jarvis MJ, Thompson N, Wadsworth MEJ (2003) Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Public Health 93:994–998PubMedCentralPubMedCrossRef Richards M, Jarvis MJ, Thompson N, Wadsworth MEJ (2003) Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Public Health 93:994–998PubMedCentralPubMedCrossRef
10.
go back to reference Anstey KJ, von Sanden C, Salim A, O’Kearney R (2007) Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Epidemiol 166:367–378PubMedCrossRef Anstey KJ, von Sanden C, Salim A, O’Kearney R (2007) Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Epidemiol 166:367–378PubMedCrossRef
11.
go back to reference Stampfer MJ (2006) Cardiovascular disease and Alzheimer’s disease: common links. J Intern Med 260:211–223PubMedCrossRef Stampfer MJ (2006) Cardiovascular disease and Alzheimer’s disease: common links. J Intern Med 260:211–223PubMedCrossRef
12.
go back to reference Umegaki H, Kawamura T, Umemura T, Kawano N (2015) Factors associated with cognitive decline in older adults with type 2 diabetes mellitus during a 6-year observation. Geriatr Gerontol Int 15:302–310PubMedCrossRef Umegaki H, Kawamura T, Umemura T, Kawano N (2015) Factors associated with cognitive decline in older adults with type 2 diabetes mellitus during a 6-year observation. Geriatr Gerontol Int 15:302–310PubMedCrossRef
13.
go back to reference Bruce DG, Davis WA, Starkstein SE, Davis TM (2014) Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: The Fremantle Diabetes Study. J Alzheimers Dis 42(Suppl 3):S63–S70PubMed Bruce DG, Davis WA, Starkstein SE, Davis TM (2014) Mid-life predictors of cognitive impairment and dementia in type 2 diabetes mellitus: The Fremantle Diabetes Study. J Alzheimers Dis 42(Suppl 3):S63–S70PubMed
14.
go back to reference Marioni RE, Strachan MWJ, Reynolds RM et al (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes The Edinburgh Type 2 Diabetes Study. Diabetes Care 59:710–713CrossRef Marioni RE, Strachan MWJ, Reynolds RM et al (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes The Edinburgh Type 2 Diabetes Study. Diabetes Care 59:710–713CrossRef
16.
go back to reference Millan J, Pinto X, Munoz A et al (2009) Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 5:757–765PubMedCentralPubMed Millan J, Pinto X, Munoz A et al (2009) Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 5:757–765PubMedCentralPubMed
17.
go back to reference Wechsler D (1997) Wechsler adult intelligence scale-3rd edition (WAIS-III). Pearson, San Antonio Wechsler D (1997) Wechsler adult intelligence scale-3rd edition (WAIS-III). Pearson, San Antonio
18.
go back to reference Wechsler D (1987) Manual of the Wechsler memory scale-revised. The Psychological Corporation Limited, New York Wechsler D (1987) Manual of the Wechsler memory scale-revised. The Psychological Corporation Limited, New York
19.
go back to reference Raven J, Raven JC, Court JH (1998) Manual for Raven’s progressive matrices and vocabulary scales. Oxford Psychologists Press Limited, Oxford Raven J, Raven JC, Court JH (1998) Manual for Raven’s progressive matrices and vocabulary scales. Oxford Psychologists Press Limited, Oxford
20.
go back to reference Yuspeh RL, Vanderploeg RD (2000) Spot-the-word: a measure for estimating premorbid intellectual functioning. Arch Clin Neuropsychol 15:319–326PubMed Yuspeh RL, Vanderploeg RD (2000) Spot-the-word: a measure for estimating premorbid intellectual functioning. Arch Clin Neuropsychol 15:319–326PubMed
21.
go back to reference Deary IJ, Whalley LJ, Crawford JR (2004) An 'instantaneous' estimate of a lifetime’s cognitive change. Intelligence 32:113–119CrossRef Deary IJ, Whalley LJ, Crawford JR (2004) An 'instantaneous' estimate of a lifetime’s cognitive change. Intelligence 32:113–119CrossRef
22.
go back to reference Spearman C (1904) 'General intelligence', objectively determined and measured. Am J Psychol 15:201–292CrossRef Spearman C (1904) 'General intelligence', objectively determined and measured. Am J Psychol 15:201–292CrossRef
23.
go back to reference Willett JB (1997) Measuring change: what individual growth modeling buys you. In: Amsel E, Renninger KA (eds) Change and development: issues of theory, method, and application. Lawrence Erlbaum Associates Inc., Mahwah, pp 213–243 Willett JB (1997) Measuring change: what individual growth modeling buys you. In: Amsel E, Renninger KA (eds) Change and development: issues of theory, method, and application. Lawrence Erlbaum Associates Inc., Mahwah, pp 213–243
24.
go back to reference Elias PK, Elias MF, D’Agostino RB et al (1997) NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 20:1388–1395PubMedCrossRef Elias PK, Elias MF, D’Agostino RB et al (1997) NIDDM and blood pressure as risk factors for poor cognitive performance. The Framingham Study. Diabetes Care 20:1388–1395PubMedCrossRef
25.
go back to reference Lee YJ, Kang HM, Kim NK et al (2014) Factors associated for mild cognitive impairment in older Korean adults with type 2 diabetes mellitus. Diabetes Metab J 38:150–157PubMedCentralPubMedCrossRef Lee YJ, Kang HM, Kim NK et al (2014) Factors associated for mild cognitive impairment in older Korean adults with type 2 diabetes mellitus. Diabetes Metab J 38:150–157PubMedCentralPubMedCrossRef
26.
go back to reference De Wet H, Levitt N, Tipping B (2007) Executive cognitive impairment detected by simple bedside testing is associated with poor glycaemic control in type 2 diabetes. S Afr Med J 97:1074–1076PubMed De Wet H, Levitt N, Tipping B (2007) Executive cognitive impairment detected by simple bedside testing is associated with poor glycaemic control in type 2 diabetes. S Afr Med J 97:1074–1076PubMed
27.
go back to reference Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME et al (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32:221–226PubMedCentralPubMedCrossRef Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME et al (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32:221–226PubMedCentralPubMedCrossRef
28.
go back to reference Rawlings AM, Sharrett AR, Schneider ALC et al (2014) Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 161:785–793PubMedCentralPubMedCrossRef Rawlings AM, Sharrett AR, Schneider ALC et al (2014) Diabetes in midlife and cognitive change over 20 years: a cohort study. Ann Intern Med 161:785–793PubMedCentralPubMedCrossRef
29.
30.
go back to reference Johnson ML, Parikh N, Kunik ME et al (2012) Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement 8:437–444PubMedCrossRef Johnson ML, Parikh N, Kunik ME et al (2012) Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement 8:437–444PubMedCrossRef
31.
go back to reference Launer LJ, Miller ME, Williamson JD et al (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 10:969–977PubMedCentralPubMedCrossRef Launer LJ, Miller ME, Williamson JD et al (2011) Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol 10:969–977PubMedCentralPubMedCrossRef
32.
go back to reference Feinkohl I, Aung PP, Keller M et al (2014) Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 37:507–515PubMedCrossRef Feinkohl I, Aung PP, Keller M et al (2014) Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 37:507–515PubMedCrossRef
33.
go back to reference Whitmer RA, Karter AJ, Yaffe K, Quesenberry CPJ, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes. JAMA 301:1565–1572PubMedCentralPubMedCrossRef Whitmer RA, Karter AJ, Yaffe K, Quesenberry CPJ, Selby JV (2009) Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes. JAMA 301:1565–1572PubMedCentralPubMedCrossRef
34.
35.
go back to reference Biessels GJ (2014) Hypoglycemia and cognitive decline in older people with type 2 diabetes: a bidirectional relationship. Diabet Hypoglycemia 6:11–14 Biessels GJ (2014) Hypoglycemia and cognitive decline in older people with type 2 diabetes: a bidirectional relationship. Diabet Hypoglycemia 6:11–14
36.
go back to reference Almeida OP, Garrido GJ, Alfonso H et al (2011) 24-month effect of smoking cessation on cognitive function and brain structure in later life. Neuroimage 55:1480–1489PubMedCrossRef Almeida OP, Garrido GJ, Alfonso H et al (2011) 24-month effect of smoking cessation on cognitive function and brain structure in later life. Neuroimage 55:1480–1489PubMedCrossRef
38.
go back to reference Williamson JD, Launer LJ, Bryan RN et al (2014) Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med 174:324–333PubMedCentralPubMedCrossRef Williamson JD, Launer LJ, Bryan RN et al (2014) Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern Med 174:324–333PubMedCentralPubMedCrossRef
39.
go back to reference Niu M-J, Yin F-Z, Liu L-X, Fang Y, Xuan X-M, Wu G-F (2013) Non-high-density lipoprotein cholesterol and other risk factors of mild cognitive impairment among Chinese type 2 diabetic patients. J Diabetes Complications 27:443–446PubMedCrossRef Niu M-J, Yin F-Z, Liu L-X, Fang Y, Xuan X-M, Wu G-F (2013) Non-high-density lipoprotein cholesterol and other risk factors of mild cognitive impairment among Chinese type 2 diabetic patients. J Diabetes Complications 27:443–446PubMedCrossRef
40.
go back to reference Reijmer YD, van den Berg E, Dekker JM et al (2012) Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 60:1426–1433PubMedCrossRef Reijmer YD, van den Berg E, Dekker JM et al (2012) Development of vascular risk factors over 15 years in relation to cognition: the Hoorn Study. J Am Geriatr Soc 60:1426–1433PubMedCrossRef
41.
go back to reference Johnson W, Te Nijenhuis J, Bouchard TJ (2008) Still just 1 g: consistent results from five test batteries. Intelligence 36:81–95CrossRef Johnson W, Te Nijenhuis J, Bouchard TJ (2008) Still just 1 g: consistent results from five test batteries. Intelligence 36:81–95CrossRef
42.
go back to reference Deary IJ, Penke L, Johnson W (2010) The neuroscience of human intelligence differences. Nat Rev Neurosci 11:201–211PubMed Deary IJ, Penke L, Johnson W (2010) The neuroscience of human intelligence differences. Nat Rev Neurosci 11:201–211PubMed
Metadata
Title
Cardiovascular risk factors and cognitive decline in older people with type 2 diabetes
Authors
Insa Feinkohl
Markéta Keller
Christine M. Robertson
Joanne R. Morling
Stela McLachlan
Brian M. Frier
Ian J. Deary
Mark W. J. Strachan
Jackie F. Price
Publication date
01-07-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3581-0

Other articles of this Issue 7/2015

Diabetologia 7/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.